Vitality Watch

Dossier pubmed preclinical 14-nov-2026
Animal model, organoid, or cell-culture result — not yet human

Identification of mitophagy inducers for Alzheimer’s disease via high-throughput endogenous ATP5B tagging system.

Key claim: An endogenous ATP5B-tagging screening platform identified the FDA-approved drug flupentixol as a novel mitophagy inducer that activates mitochondrial AMPK and ameliorates cognitive deficits and pathology in an Alzheimer’s disease mouse model.

Abstract

INTRODUCTION: Mitophagy, the selective clearance of defective mitochondria via the autophagy-lysosome pathway, is essential for maintaining mitochondrial health and cellular homeostasis. Dysregulation of mitophagy is strongly implicated in aging-related pathologies, including neurodegenerative diseases (Alzheimer’s, Parkinson’s), cancer, and metabolic disorders, highlighting the significance of elucidating its regulatory mechanisms. While existing methods using exogenous reporters enable genome-wide and high-throughput screening for mitophagy regulators, they constrain discoveries to specific pathways and introduce artifacts through ectopic expression. OBJECTIVES: To overcome these limitations, we developed an effective and rapid platform for identifying mitophagy modulators by targeting endogenous proteins. METHODS: Using CRISPR-Cas9 technology, we engineered HeLa cells expressing small molecular tags (GFP or NanoLuc) fused to the C-terminal of ATP5B, a mitochondrial inner membrane protein. Genome-wide screening for mitophagy regulatory genes were performed using a genome-wide CRISPR library coupled with flow cytometry. Additionally, an FDA-approved kinase inhibitor library was used to screen for mitophagy inducers. To evaluate the efficacy of a screened drug in Alzheimer’s disease, cognitive behavior, pathological features and mitophagy events in 3 × Tg-AD mice with or without treatment were examined using the Morris water maze assay, enzyme-linked immunosorbent assay (ELISA) and transmission electron microscopy (TEM). RESULTS: These ATP5B-tagging cells provided a robust readout of mitophagy and enabled high-throughput genetic or pharmacological screening. With this platform, we identified several promising genes that regulate mitophagy and are significantly associated with Alzheimer’s disease. Moreover, the FDA-approved drug Flupentixol emerged as a novel mitophagy inducer that acts by promoting adenosine monophosphate-activated protein kinase (AMPK) localization to mitochondria and exhibited strong therapeutic potential in a model of Alzheimer’s disease. CONCLUSION: This study establishes a novel system for identifying mitophagy modulators, with the potential to accelerate the discovery of therapeutic strategies for Alzheimer’s disease.

Why this matters

[animal-model] This study adds mitochondrial AMPK recruitment and activation to the candidate routes linking pharmacologically induced mitophagy with improved cognition and pathology in an Alzheimer’s mouse model, without establishing canonical PINK1–Parkin dependence. [mechanism-plausible] Endogenous ATP5B tagging is designed to reduce overexpression-related screening artifacts, but that methodological rationale does not establish clinical predictive validity; the flupentixol-repurposing narrative remains separated from demonstrated human Alzheimer’s or healthy-aging benefit.

Source

Link

Briefing card

Identification of mitophagy inducers for Alzheimer's disease via high-throughput endogenous ATP5B tagging system.
Stage: preclinical · pubmed · 14-nov-2026

If you take flupentixol, this study's reported cognitive benefits were in mice, not people.

An endogenous ATP5B-tagging screening platform identified the FDA-approved drug flupentixol as a novel mitophagy inducer that activates mitochondrial AMPK and ameliorates cognitive deficits and pathology in an Alzheimer's disease mouse model.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.jare.2026.11.015

build build 880 · 2bcef25 · 2026-11-18